Exosome-Loaded Pro-efferocytic Vascular Stent with Lp-PLA₂-Triggered Release for Preventing In-Stent Restenosis

Abstract

The efferocytosis defect is regarded as a pivotal event of atherosclerosis. The failure to clear apoptotic cells in atherosclerotic plaques under vascular stents causes a failure to resolve the inflammation underneath. However, efferocytosis repair is still confined to nonstenting therapeutics. Here, we identified a pro-efferocytotic agent and accordingly developed a bioresponsive pro-efferocytotic vascular stent aimed for poststenting healing. Exosomes derived from mesenchymal stem cells were found to be able to regulate efferocytosis via SLC2a1, STAT3/RAC1, and CD300a pathways and modulate foam cell formation processes through a CD36-mediated pathway. Pro-efferocytotic exosomes were encapsulated into liposome-based multivesicular chambers and grafted onto vascular stents. The multivesicular vesicles were able to release exosomes under the Lp-PLA2 environment. Compared to bare metal stents, exosome-stents in the presence of Lp-PLA2 enhanced the ratio of apoptotic cell clearance and reduced the neointimal thickness in the mal-efferocytotic rat model. Overall, we identified a pro-efferocytic agentexosomes that are able to regulate target cells via multiple signaling pathways and are good candidates to serve complex pathological environments, and this bioresponsive pro-efferocytotic vascular stent is an attractive approach for prevention of poststenting complications.

Exosomal Non-Coding RNAs: Novel Regulators of Macrophage-Linked Intercellular Communication in Lung Cancer and Inflammatory Lung Diseases

“…Some miRNA-based therapies are being examined in clinical trials, such as TargomiR (miR-16 mimic-based therapy) for malignant pleural mesothelioma [ 142 ] and Miravirsen (anti-miR-122 based therapy) for hepatitis C virus infection [ 143 ]. Accumulative evidence suggests that exosomes can be processed and used as drug carriers [ 144 , 145 ]. Immunotherapy is currently the most promising treatment strategy against cancers since tumor immune evasion is a crucial stage in the malignant growth of tumors and one of the main obstacles to it.…”

Restoring endothelial function: shedding light on cardiovascular stent development

“…12C). 167 In the case of high-level lipoprotein-associated phospholipase A2 (Lp-PLA2) caused by inflammation, EES would release MSC-XOs to enhance the ratio of apoptotic cell clearance and decrease the neointimal thickness in the mal-efferocytosis rat model. Compared with the BMS and DES, the designed EES showed obvious advantage in repressing the hyperplasia of VSMCs and reducing the risk of delayed reendothelialization.…”

Nature-inspired nanocarriers for improving drug therapy of atherosclerosis

“…Zou et al . successfully extracted MSCs-Exos and encapsulated them with liposomes to construct multivesicular vesicles (MVVs) [ 112 ]. To this end, MVVs were grafted onto eluting vascular stent for AS treatment.…”